Adezunap (AP707)

DRUG7 trials

Sponsors

Apurano Pharmaceuticals GmbH

Conditions

Back PainCentral Neuropathic PainChronic PainChronic Pain SyndromeDiabetesDiabetic NeuropathiesDiabetic PolyneuropathyLower Back Pain

Phase 3

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Apurano Pharmaceuticals GmbHChronic Pain, Chronic Pain Syndrome, Diabetes +8

Start: 2023-11-02End: 2024-12-31Target: 558Updated: 2024-01-31

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Apurano Pharmaceuticals GmbHBack Pain, Chronic Pain, Chronic Pain Syndrome +5

Start: 2023-11-02End: 2024-12-31Target: 558Updated: 2024-01-31

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Apurano Pharmaceuticals GmbHChronic Pain, Chronic Pain Syndrome, Neuropathic Pain +9

Start: 2023-11-02End: 2024-12-31Target: 558Updated: 2024-01-31

Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Apurano Pharmaceuticals GmbHBack Pain, Chronic Pain, Chronic Pain Syndrome +5

Start: 2023-11-02End: 2024-12-31Target: 558Updated: 2024-01-31

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Apurano Pharmaceuticals GmbHChronic Pain, Chronic Pain Syndrome, Diabetes +8

Start: 2023-11-02End: 2024-12-31Target: 558Updated: 2024-01-31

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Apurano Pharmaceuticals GmbHChronic Pain, Chronic Pain Syndrome, Neuropathic Pain +9

Start: 2023-11-02End: 2024-12-31Target: 558Updated: 2024-01-31

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Apurano Pharmaceuticals GmbHCentral Neuropathic Pain, Chronic Pain, Chronic Pain Syndrome +10

Start: 2023-11-02End: 2024-12-31Target: 558Updated: 2024-01-31